论文部分内容阅读
选取2012-2014年我院糖尿病门诊筛查的糖尿病前期患者80例,随机分为观察组和对照组。对照组通过饮食控制、健康教育、运动治疗,观察组加用二甲双胍治疗。结果两组治疗前的空腹血糖(FBG)、餐后2h血糖(2h PG)、糖化血红蛋白(HbA_(1C))、胰岛素抵抗指数(HOMA-IR)及体重指数(BMI)水平无明显差异;治疗后观察组的FBG为(5.56±0.84)mmol/L,2h PG为(8.02±1.15)mmol/L,HbA_(1C)为(5.42±0.56)%,HOMA-IR(1.45±0.28)及BMI(24.52±3.06)kg/m~2均明显低于对照组(P<0.01)。结论二甲双胍治疗糖尿病前期可更好地降低患者的FBG、2h PG、HbAlc、HOMA-IR及BMI指标水平,疗效明显。
Eighty pre-diabetic patients who were screened out from our diabetes clinic in 2012-2014 were randomly divided into observation group and control group. The control group through diet control, health education, exercise therapy, observation group plus metformin treatment. Results There were no significant differences in fasting blood glucose (FBG), 2h PG, HbA 1c, HOMA-IR and BMI before treatment in both groups. After treatment, FBG in the observation group was (5.56 ± 0.84) mmol / L, PG in 2 h was (8.02 ± 1.15) mmol / L, HbA 1 was 5.42 ± 0.56%, HOMA-IR was 1.45 ± 0.28, 24.52 ± 3.06) kg / m ~ 2 were significantly lower than those in the control group (P <0.01). Conclusion Metformin treatment of pre-diabetes can be better in patients with FBG, 2h PG, HbAlc, HOMA-IR and BMI index levels, the effect is obvious.